MX2018013410A - Composiciones y metodos para proporcionar la hormona tiroidea o analogos de la misma. - Google Patents

Composiciones y metodos para proporcionar la hormona tiroidea o analogos de la misma.

Info

Publication number
MX2018013410A
MX2018013410A MX2018013410A MX2018013410A MX2018013410A MX 2018013410 A MX2018013410 A MX 2018013410A MX 2018013410 A MX2018013410 A MX 2018013410A MX 2018013410 A MX2018013410 A MX 2018013410A MX 2018013410 A MX2018013410 A MX 2018013410A
Authority
MX
Mexico
Prior art keywords
thyroid hormone
analogs
methods
compositions
providing
Prior art date
Application number
MX2018013410A
Other languages
English (en)
Inventor
Tengler Mark
Original Assignee
Spectrix Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spectrix Therapeutics Llc filed Critical Spectrix Therapeutics Llc
Publication of MX2018013410A publication Critical patent/MX2018013410A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/78—Thyroid gland hormones, e.g. T3, T4, TBH, TBG or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/046—Thyroid disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención incluye una composición farmacéutica y métodos para elaborar y utilizar una composición farmacéutica que comprende una o más hormona(s) tiroidea(s) o análogos de la(s) misma(s), en donde una primera porción de la(s) hormona(s) tiroidea(s) se formula para liberación inmediata y una segunda porción de la(s) hormona(s) tiroidea(s) se formula para liberación modificada, e.g., al formar una partícula de fármaco-resina con una resina de intercambio iónico.
MX2018013410A 2016-05-03 2017-05-01 Composiciones y metodos para proporcionar la hormona tiroidea o analogos de la misma. MX2018013410A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662331148P 2016-05-03 2016-05-03
US201662344271P 2016-06-01 2016-06-01
PCT/US2017/030435 WO2017192458A1 (en) 2016-05-03 2017-05-01 Compositions and methods of providing thyroid hormone or analogs thereof
US15/583,695 US20170319526A1 (en) 2016-05-03 2017-05-01 Compositions and methods of providing thyroid hormone or analogs thereof

Publications (1)

Publication Number Publication Date
MX2018013410A true MX2018013410A (es) 2019-06-06

Family

ID=60203317

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013410A MX2018013410A (es) 2016-05-03 2017-05-01 Composiciones y metodos para proporcionar la hormona tiroidea o analogos de la misma.

Country Status (9)

Country Link
US (2) US20170319526A1 (es)
JP (2) JP2019515045A (es)
KR (3) KR102338803B1 (es)
AU (2) AU2017261225B2 (es)
BR (1) BR112018072602A2 (es)
CA (1) CA3022933A1 (es)
IL (1) IL262729A (es)
MX (1) MX2018013410A (es)
WO (1) WO2017192458A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9782376B1 (en) 2016-12-01 2017-10-10 Fresenius Kabi Usa Llc Levothyroxine liquid formulations
WO2019094292A1 (en) * 2017-11-09 2019-05-16 Spectrix Therapeutics, LLC Compositions and methods of providing thyroid hormone of analogs thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225204A (en) * 1991-11-05 1993-07-06 Chen Jivn Ren Stable dosage of levothyroxine sodium and process of production
DK0550108T3 (da) * 1991-12-30 1999-01-04 Akzo Nobel Nv Thyreoaktiv sammensætning med langvarig frigivelse
GB9401892D0 (en) * 1994-02-01 1994-03-30 Boots Co Plc Therapeutic agents
JP2004525109A (ja) * 2001-02-15 2004-08-19 キング・ファーマシューティカルズ・インコーポレイティッド 安定化された甲状腺ホルモン医薬組成物、及びその製法
WO2004041208A2 (en) * 2002-11-05 2004-05-21 New River Pharmaceuticals Inc. Controlled absorption of mixed thyroyd hormone formulations
US8668926B1 (en) * 2003-09-15 2014-03-11 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
US20050181050A1 (en) * 2004-01-28 2005-08-18 Collegium Pharmaceutical, Inc. Dosage forms using drug-loaded ion exchange resins
WO2005084627A1 (en) * 2004-03-01 2005-09-15 University Of Iowa Research Foundation Alcohol-free chlorhexidine compositions
ES2308065T3 (es) * 2004-04-30 2008-12-01 Topotarget Germany Ag Formulacion que comprende un inhibidor de histona desacetilasa, que exhibe una liberacion bifasica.
EP1846040A2 (en) * 2005-01-28 2007-10-24 Collegium Pharmaceutical, Inc. Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents
AU2006230557A1 (en) * 2005-03-31 2006-10-05 King Pharmaceuticals Research & Development, Inc. Controlled release pharmaceutical compositions of liothyronine and methods of making and using the same
US8343546B2 (en) * 2005-09-13 2013-01-01 Coating Place, Inc. Ion exchange resin treated to control swelling
US20090022806A1 (en) * 2006-12-22 2009-01-22 Mousa Shaker A Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof
EP2428205B1 (en) * 2006-03-16 2012-10-03 Tris Pharma, Inc. Modified release formulations containing drug-ion exchange resin complexes
WO2008057464A2 (en) * 2006-11-01 2008-05-15 King Pharmaceuticals Research And Development, Inc. Compositions and methods for improving the bioavailability of liothyronine
CA2689101C (en) * 2007-05-30 2013-01-22 Neos Therapeutics, Lp Modifying drug release in suspensions of ionic resin systems
KR101609279B1 (ko) * 2008-03-21 2016-04-05 밀란 파마슈티컬즈, 인코포레이티드 왁스를 포함하는 서방형 제형
CA2757337A1 (en) * 2009-04-03 2010-10-07 Coating Place, Inc. Modified-release pharmaceutical drug composition
WO2013003622A1 (en) * 2011-06-28 2013-01-03 Neos Therapeutics, Lp Dosage forms for oral administration and methods of treatment using the same
JP2014525423A (ja) * 2011-08-30 2014-09-29 ウニベルシテイト ヘント 多層放出配合物

Also Published As

Publication number Publication date
KR20210154264A (ko) 2021-12-20
US20170319526A1 (en) 2017-11-09
BR112018072602A2 (pt) 2019-02-19
IL262729A (en) 2018-12-31
WO2017192458A1 (en) 2017-11-09
CA3022933A1 (en) 2017-11-09
NZ748508A (en) 2020-11-27
KR20200110396A (ko) 2020-09-23
AU2020204558A1 (en) 2020-07-30
AU2017261225A1 (en) 2018-12-13
KR102338803B1 (ko) 2021-12-14
AU2017261225B2 (en) 2020-04-09
US20190133982A1 (en) 2019-05-09
JP2019515045A (ja) 2019-06-06
KR20180132955A (ko) 2018-12-12
JP2021073275A (ja) 2021-05-13

Similar Documents

Publication Publication Date Title
CO2018003134A2 (es) Composiciones para el cuidado bucal que comprenden un aminoácido básico, una combinación de fuentes de iones de zinc y un sistema quelante
CL2020002801A1 (es) Anticuerpos monoclonales contra bcma (divisional de solicitud 201800281).
CL2016002772A1 (es) Composiciones de insulina de rápida acción
MX2019003735A (es) Formulaciones diluibles de cannabinoides y procesos para su preparacion.
MX2021002455A (es) Metodos para tratar tumores de celulas epitelioides.
CU20190058A7 (es) Composiciones de aminoácidos relacionadas con mejoras de la función hepática
MX2022015755A (es) Profarmacos de hormona paratiroidea (pth).
MX2020001525A (es) Composiciones de peptido similar al glucagon tipo 1 (glp-1) y sus usos.
MX2018015272A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
MX2018015268A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
MX2019001121A (es) Nuevas formulaciones y composiciones de cannabis en comprimidos y metodos para su elaboracion.
MX2018015274A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
MX2017004975A (es) Composiciones de anticuerpos anti-il-7r.
MX2018016362A (es) Formulaciones de anticuerpo anti-cd19.
MX2021010783A (es) Formulaciones de anticuerpo anti-il-36r.
EA201591196A1 (ru) Композиции и способы для трансдермальной доставки гормонов и других лекарственных средств
MX2020002123A (es) Sales de ribociclib y formas en estado sólido de las mismas.
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
EA031255B8 (ru) Состав с отсроченным высвобождением, содержащий гранулы цистеамина, и способы его получения и применения
TN2015000319A1 (en) Oxidatively curable coating composition
CL2018003587A1 (es) Composición de cal apagada en polvo altamente porosa.
SG11201809835UA (en) Method for manufacturing acetaminophen preparation
MX2018008581A (es) Cemento de fosfato de magnesio.
EP3688033A4 (en) NEW FORMULATIONS THAT STABILIZE LOW DOSE ANTIBODY COMPOSITIONS
MX2018013410A (es) Composiciones y metodos para proporcionar la hormona tiroidea o analogos de la misma.